Get App
Download App Scanner
Scan to Download
Advertisement

Rubicon Research: Motilal Oswal Revises Target Price After Arinna Lifesciences Deal — Should You Buy, Sell, Hold?

Rubicon Research has not only strengthened its capabilities across research and development, manufacturing, and commercialisation through bolt-on acquisitions, but has also scaled up meaningfully to maximise return on investments.

Rubicon Research: Motilal Oswal Revises Target Price After Arinna Lifesciences Deal — Should You Buy, Sell, Hold?
While Arinna's products will be added to Rubicon's portfolio, the key advantage of this acquisition would include gaining access to an established network of distributors, stockists, and retail pharmacies in India, along with a strong prescriber base.
(Photo: Company website)
STOCKS IN THIS STORY
Rubicon Research Ltd
--

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Rubicon Research Ltd. has not only strengthened its capabilities across research and development, manufacturing, and commercialisation through bolt-on acquisitions, but has also scaled up meaningfully to maximize return on investments.

From ~Rs 40 crore in FY15, Rubicon has scaled its business to Rs 1,600 crore over FY15- TTM ending Dec'25.

The company has built full-spectrum capabilities comprising specialty products, drug-device combinations (Nasal sprays), complex generics, wide basket of 74 an abbreviated new drug application/9 NDAs, and sales/marketing capabilities for branded/non-branded products in the US market.

This is not only supported by a differentiated R&D approach but also robust manufacturing capabilities.

The prescriber base and established distribution network are key for brand-led profitable growth in the domestic formulation space. Rubicon is rightly building the foundation for growth prospects in the DF segment. 

The brokerage has raised its P/E multiple from 35x to 37x, factoring in the potential upside from earnings. Accordingly, revises the target price to Rs 955. Reiterates Buy.

Click on the attachment to read the full report:

Motilla Oswal Rubicon Update.pdf
VIEW DOCUMENT

ALSO READ: MTAR Tech: Target Price Raised By Motilal Oswal After Bloom-Oracle AI Data Centre Deal — Check Potential Upside

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Add NDTV Profit As Google Preferred Source
Loading PDF...